Hemo Organic Ltd. | Small-cap | Healthcare
₹9.26
-9.83%
| Hemo Organic Stock Comparison:
Hemo Organic vs Sun PharmaceuticalHemo Organic vs Divi's LaboratoriesHemo Organic vs Innova CaptabHemo Organic vs Sequent ScientificHemo Organic vs Sun Pharma AdvancedHemo Organic vs NIFTY 50 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 19.0K
Gross Profit 5.0K 26.32%
Operating Income -1.1M -6,026.32%
Net Income -857.0K -4,510.53%
EPS (Diluted) ₹-0.25

Balance Sheet Metrics

Total Assets 49.7M
Total Liabilities 51.3M
Shareholders Equity -1.5M

Cash Flow Metrics

Revenue & Profitability Trend

Hemo Organic Income Statement From 2021 to 2025

Metric20252024202320222021
Revenue i24.1M224.0K48.0K68.3K80.7K
Cost of Goods Sold i22.0M153.0K16.0K93.2K45.0K
Gross Profit i2.1M71.0K32.0K-24.9K35.7K
Gross Margin % i8.9%31.7%66.7%-36.5%44.3%
Operating Expenses
Research & Development i-----
Selling, General & Administrative i-2.0M577.0K237.1K123.1K
Other Operating Expenses i2.3M75.0K578.0K238.0K9.0K
Total Operating Expenses i2.3M2.1M1.2M475.1K132.0K
Operating Income i-443.0K-2.4M-545.0K-622.0K-477.3K
Operating Margin % i-1.8%-1,088.4%-1,135.4%-910.7%-591.5%
Non-Operating Items
Interest Income i-----
Interest Expense i0202.0K01.0K160
Other Non-Operating Income-----
Pre-tax Income i256.0K-2.6M-546.0K-623.7K-478.7K
Income Tax i-1.4M0000
Effective Tax Rate % i-540.2%0.0%0.0%0.0%0.0%
Net Income i1.6M-2.6M-546.0K-623.7K-478.7K
Net Margin % i6.8%-1,179.0%-1,137.5%-913.1%-593.2%
Key Metrics
EBITDA i256.0K-2.4M-546.0K-622.6K-478.6K
EPS (Basic) i₹0.47₹-0.76₹-0.16₹-0.18₹-0.14
EPS (Diluted) i₹0.47₹-0.76₹-0.16₹-0.18₹-0.14
Basic Shares Outstanding i34872343465900346590034659003465900
Diluted Shares Outstanding i34872343465900346590034659003465900

Income Statement Trend

Hemo Organic Balance Sheet From 2021 to 2025

Metric20252024202320222021
Assets
Current Assets
Cash & Equivalents i87.0K1.3M523.0K4.5K44.0K
Short-term Investments i--643.0K87.8K92.6K
Accounts Receivable i25.2M827.0K592.0K591.7K669.7K
Inventory i14.2M0153.0K168.8K23.3K
Other Current Assets7.5M7.1M35.0K41.0K7.0K
Total Current Assets i46.9M9.2M2.0M965.4K908.2K
Non-Current Assets
Property, Plant & Equipment i20.0K20.0K20.0K20.0K-
Goodwill i00000
Intangible Assets i-----
Long-term Investments-----
Other Non-Current Assets-1.0K---
Total Non-Current Assets i2.8M1.4M1.4M1.4M1.4M
Total Assets i49.7M10.6M3.4M2.4M2.3M
Liabilities
Current Liabilities
Accounts Payable i36.3M1.1M1.1M1.1M802.6K
Short-term Debt i0000-
Current Portion of Long-term Debt-----
Other Current Liabilities84.0K267.0K1.8M489.6K180.0K
Total Current Liabilities i36.5M1.4M3.6M2.0M1.3M
Non-Current Liabilities
Long-term Debt i14.8M12.4M352.0K350.4K350.4K
Deferred Tax Liabilities i5.0K000-
Other Non-Current Liabilities--1.0K-100-
Total Non-Current Liabilities i14.8M12.4M352.0K350.6K350.4K
Total Liabilities i51.3M13.8M4.0M2.4M1.7M
Equity
Common Stock i34.7M34.7M34.7M34.7M34.7M
Retained Earnings i--37.8M-35.2M-34.6M-34.0M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i-1.5M-3.2M-512.0K34.2K658.0K
Key Metrics
Total Debt i14.8M12.4M352.0K350.4K350.4K
Working Capital i10.5M7.8M-1.6M-1.0M-417.0K

Balance Sheet Composition

Hemo Organic Cash Flow Statement From 2021 to 2025

Metric20252024202320222021
Operating Activities
Net Income i256.0K-2.6M-546.0K-623.7K-478.7K
Depreciation & Amortization i-----
Stock-Based Compensation i-----
Working Capital Changes i-39.2M-9.1M1.6M270.2K532.4K
Operating Cash Flow i-38.9M-11.7M1.1M-353.5K53.6K
Investing Activities
Capital Expenditures i-----
Acquisitions i-----
Investment Purchases i-0000
Investment Sales i-----
Investing Cash Flow i-0000
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i2.4M0000
Debt Repayment i--000
Financing Cash Flow i2.4M12.0M2.0K00
Free Cash Flow i-3.6M-11.9M1.1M-44.3K-137.7K
Net Change in Cash i-36.5M325.0K1.1M-353.5K53.6K

Cash Flow Trend

Hemo Organic Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 44.87
Price to Book -21.72
Price to Sales 1.44
PEG Ratio 0.02

Profitability Ratios

Profit Margin 3.28%
Operating Margin -6,026.32%
Return on Equity -108.18%
Return on Assets 3.29%

Financial Health

Current Ratio 1.29
Debt to Equity -9.77
Beta -0.06

Per Share Data

EPS (TTM) ₹0.23
Book Value per Share ₹-0.44
Revenue per Share ₹7.06

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
hemorganic33.5M44.87-21.72-108.18%3.28%-9.77
Sun Pharmaceutical 3.9T37.285.3715.08%19.29%3.26
Divi's Laboratories 1.6T69.8010.7414.64%23.89%0.03
Innova Captab 49.4B37.875.1213.37%9.98%35.24
Sequent Scientific 46.9B157.766.442.84%1.85%62.47
Sun Pharma Advanced 46.7B-13.68-21.57157.88%-53.22%-1.24

Financial data is updated regularly. All figures are in the company's reporting currency.